激活循环氧化原酶-2 信号介导体,通过利拉格卢提德诱导的脂肪脂解活性进行介导
Jingyi Li1, Hailian Wu1, Wenhui Ma1
1Department of Pathophysiology, School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China.
European journal of pharmacology
|September 11, 2025
概括
利拉格卢提德是一种GLP-1RA,通过通过循环氧化酶-2 (COX-2) 信号传递来减少脂肪细胞来改善代谢健康. 这一途径对其对脂肪组织的影响和对寒冷的反应至关重要,为肥胖治疗提供了临床见解.
科学领域:
- 代谢研究研究 代谢研究
- 脂肪组织生物学 脂肪组织生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 主要有助于减肥.
- GLP-1RA对脂肪组织平衡作用的新机制需要阐明.
- 循环氧化酶-2 (COX-2) 信号在新陈代谢调节中的作用是一个值得关注的领域.
研究的目的:
- 为了研究利拉格卢提德对脂肪组织恒温的影响.
- 确定循环氧化酶 (COX) - 2信号传递在利拉格卢提德代谢效益中的作用.
- 探索利拉格卢提德对脂肪生成,脂解和热生成的影响.
主要方法:
- 在高脂肪饮食 (HFD) 诱导的肥胖小鼠中进行体内评估,这些小鼠接受了liraglutide治疗.
- 在体外研究中使用差异化脂肪细胞和3T3-L1细胞.
- 非向的代谢基因组学来识别冷暴露期间的关键代谢物和COX-2参与.
- 评估COX-2抑制对利拉格卢提德的作用.
主要成果:
- 利拉格卢提德改善了胰岛素耐药性,降低了身体和脂肪体重,并抑制了脂肪细胞缩.
- 观察到色标记物 (PGC1α,UCP1,ATGL) 的升级,以及COX-2信号/前列腺素水平的增加.
- 抑制COX-2抑制了liraglutide对脂肪生成,脂解和适应性热生成受损的影响.
结论:
- 利拉格卢提德通过对COX-2通路的上调抑制脂肪细胞缩.
- 脂肪组织中的COX-2信号传递是liraglutide代谢益处的关键机制.
- 针对COX-2通路对于接受GLP-1RAs治疗的肥胖患者来说是相关的.
相关概念视频
Glucagon-like Receptor Agonists
854
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
854
GPCRs Regulate Adenylyl Cylase Activity
7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
cAMP-dependent Protein Kinase Pathways
8.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.3K
Insulin: The Receptor and Signaling Pathways
2.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.8K


